{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:12:32Z","timestamp":1789776752041,"version":"4.0.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.autrev.2014.04.003","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T03:47:04Z","timestamp":1397360824000},"page":"822-830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Ignazio","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.autrev.2014.04.003_bb0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00296-005-0044-9","article-title":"The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease","volume":"26","author":"Turkcapar","year":"2006","journal-title":"Rheumatol Int"},{"issue":"12","key":"10.1016\/j.autrev.2014.04.003_bb0010","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/003655201317097173","article-title":"Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients","volume":"36","author":"Salvarani","year":"2001","journal-title":"Scand J Gastroenterol"},{"issue":"20","key":"10.1016\/j.autrev.2014.04.003_bb0015","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3748\/wjg.15.2449","article-title":"Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease","volume":"15","author":"Salvarani","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.autrev.2013.06.006","article-title":"Rheumatic manifestations in inflammatory bowel disease","volume":"13","author":"Atzeni","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.04.003_bb0025","doi-asserted-by":"crossref","first-page":"631408","DOI":"10.1155\/2013\/631408","article-title":"Enteropathic spondyloarthritis: from diagnosis to treatment","volume":"2013","author":"Peluso","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2014.04.003_bb0030","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0035","first-page":"373","article-title":"The arthritis of ulcerative colitis: clinical and genetic aspects","volume":"19","author":"Scarpa","year":"1992","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2014.04.003_bb0040","first-page":"2860","article-title":"Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association","volume":"27","author":"de Vlam","year":"2000","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2014.04.003_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11926-000-0045-3","article-title":"Arthritis and inflammatory bowel disease","volume":"2","author":"Wordsworth","year":"2000","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0050","first-page":"511","article-title":"Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study)","volume":"29","author":"Palm","year":"2002","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0055","first-page":"518","article-title":"Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease","volume":"30","author":"Steer","year":"2003","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2012.09.005","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations","volume":"7","author":"Van Assche","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"44","key":"10.1016\/j.autrev.2014.04.003_bb0065","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3748\/wjg.15.5517","article-title":"Rheumatic manifestations of inflammatory bowel disease","volume":"15","author":"Rodriguez-Reyna","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.autrev.2014.04.003_bb0070","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/rheumatology\/40.11.1256","article-title":"The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study)","volume":"40","author":"Palm","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10620-010-1260-z","article-title":"Peripheral arthritis in the course of inflammatory bowel diseases","volume":"56","author":"Yuksel","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.autrev.2014.04.003_bb0085","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/1529-0131(200112)44:12<2728::AID-ART459>3.0.CO;2-8","article-title":"Inflammatory bowel disease and spondylarthropathy","volume":"44","author":"Smale","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.autrev.2014.04.003_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1572-0241.2004.04039.x","article-title":"Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis","volume":"99","author":"Manguso","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00384-004-0626-0","article-title":"Consecutive occurrence of rhinoconjunctivitis, seronegative spondyloarthritis and pyoderma gangrenosum in a patient with ulcerative colitis","volume":"20","author":"Manguso","year":"2005","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"10.1016\/j.autrev.2014.04.003_bb0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0110","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2014.04.003_bb0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s100670070003","article-title":"Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study","volume":"19","author":"Queiro","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","article-title":"Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors","volume":"41","author":"Braun","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"7809","key":"10.1016\/j.autrev.2014.04.003_bb0125","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","article-title":"Ankylosing spondylitis and HL-A 27","volume":"1","author":"Brewerton","year":"1973","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2014.04.003_bb0130","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-136-12-200206180-00011","article-title":"Update on spondyloarthropathies","volume":"136","author":"Khan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2014.04.003_bb0135","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5463","key":"10.1016\/j.autrev.2014.04.003_bb0145","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.2.5463.670","article-title":"The arthritis of ulcerative colitis","volume":"2","author":"Wright","year":"1965","journal-title":"Br Med J"},{"issue":"30","key":"10.1016\/j.autrev.2014.04.003_bb0150","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","article-title":"Extraintestinal manifestations and complications in inflammatory bowel diseases","volume":"12","author":"Rothfuss","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.autrev.2014.04.003_bb0155","first-page":"703","article-title":"Arthritic manifestations of inflammatory bowel disease","volume":"83","author":"Gravallese","year":"1988","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2014.04.003_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2036.2004.02044.x","article-title":"Review article: joint involvement in inflammatory bowel disease","volume":"20","author":"De Vos","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0165","first-page":"23","article-title":"Destructive lesions of small joints in seronegative spondylarthropathies: relation to gut inflammation","volume":"8","author":"Mielants","year":"1990","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2014.04.003_bb0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/gut.17.11.906","article-title":"Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27)","volume":"17","author":"Mallas","year":"1976","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.autrev.2014.04.003_bb0175","first-page":"1953","article-title":"Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study","volume":"26","author":"Oostveen","year":"1999","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0180","doi-asserted-by":"crossref","first-page":"e58616","DOI":"10.1371\/journal.pone.0058616","article-title":"Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study","volume":"8","author":"Mera-Varela","year":"2013","journal-title":"PLoS One"},{"issue":"4\u20135","key":"10.1016\/j.autrev.2014.04.003_bb0185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.autrev.2014.01.029","article-title":"Diagnosis and classification of Crohn's disease","volume":"13","author":"Laass","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis","volume":"4","author":"Van Assche","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"4\u20135","key":"10.1016\/j.autrev.2014.04.003_bb0195","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2014.04.003_bb0200","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2013.06.007","article-title":"Immunity, autoimmunity and inflammatory bowel disease","volume":"13","author":"Cassinotti","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.autrev.2013.06.003","article-title":"Targets for new immunomodulation strategies in inflammatory bowel disease","volume":"13","author":"Monteleone","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease","volume":"43","author":"Orlando","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.autrev.2014.04.003_bb0230","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.autrev.2014.04.003_bb0235","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2014.04.003_bb0240","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0245","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2014.04.003_bb0250","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2014.04.003_bb0255","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.gtc.2004.02.010","article-title":"Mesalamine derivatives in the treatment of Crohn's disease","volume":"33","author":"Harrell","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"issue":"5","key":"10.1016\/j.autrev.2014.04.003_bb0260","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0265","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action","volume":"39","author":"Haraoui","year":"2009","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"15","key":"10.1016\/j.autrev.2014.04.003_bb0275","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2014.04.003_bb0280","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s001980170056","article-title":"Comparison of calcaneal ultrasound and DXA to assess the risk of corticosteroid-induced osteoporosis: a cross-sectional study","volume":"12","author":"Javaid","year":"2001","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.autrev.2014.04.003_bb0285","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.autrev.2014.04.003_bb0290","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1016\/S0016-5085(12)60794-X","article-title":"Adalimumab prevents post-operative Crohn\u2019s disease recurrence, and is superior to thiopurines: early results from the POCER study [abstract]","volume":"142","author":"De Cruz","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2014.04.003_bb0295","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents Crohn's disease recurrence after ileal resection","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.autrev.2014.04.003_bb0300","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.autrev.2014.04.003_bb0305","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.autrev.2014.04.003_bb0310","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0315","first-page":"CD004115","article-title":"Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis","author":"Marshall","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0320","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.autrev.2014.04.003_bb0325","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"2","author":"Sutherland","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.autrev.2014.04.003_bb0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2036.1995.tb00384.x","article-title":"Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis","volume":"9","author":"Marshall","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.autrev.2014.04.003_bb0335","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1053\/j.gastro.2006.03.028","article-title":"Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case\u2013control study","volume":"130","author":"Velayos","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.04.003_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2014.01.006","article-title":"Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy","author":"Monterubbianesi","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.autrev.2014.04.003_bb0350","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2014.04.003_bb0355","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases","volume":"101","author":"El Miedany","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2014.04.003_bb0360","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"issue":"5321","key":"10.1016\/j.autrev.2014.04.003_bb0365","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/bmj.2.5321.1708","article-title":"Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis","volume":"2","author":"Truelove","year":"1962","journal-title":"Br Med J"},{"key":"10.1016\/j.autrev.2014.04.003_bb0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(65)90972-4","article-title":"Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis","volume":"285","author":"Misiewicz","year":"1965","journal-title":"Lancet"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T13:24:57Z","timestamp":1565357097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1568997214001049"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.04.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}